3Zeleoetz AD,Advani RH,Bociek RG,et al.NCCN clinical practice guidelines in oncology:Nan-Hodgkin's lymphomas(V3.2007).
4Gilchrest BA,Parrish JA,Tanenbaum L,et al.Oral methoxsalen photochemotherapy of mycosis fungoides[J].Cancer,1976,38(2):683-689.
5Gupta AK,Anderson TF.Psoralen photochemotherapy[J].J Am Acad Dermatol,1987,17(5 Pt 1):703-734.
6Duvic M.Systemic monotherapy vs combination therapy for CTCL:rationale and future strategies[J].Oncology(Williston Park),2007,21 (2 Suppl 1):33-40.
7Papadavid E,Antoniou C,Nikolaou V,et al.Safety and efficacy of low--dose bexarotene and PUVA in the treatment of patients with mycosis fungoides[J].Am J Clin Dermatol,2008,9(3):169-173.
8Fantin VR,Loboda A,Paweletz CP,et al.Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma[J].Cancer Res,2008,68(10):3785-3794.
9Olsen E,Duvic M,Frankel A,et al.Pivotal phase Ⅲ trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma[J].J Clin Oncol,2001,19(2):376-388.
10Gorgun G,Foss F.Immunomodulatory effects of RXR rexinoids:modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox[J].Blood,2002,100(4):1399-1403.
